VJOncology is committed to improving our service to you

Share this video  

VJOncology is committed to improving our service to you

ESMO 2021 | NGS for the detection of mutations in NSCLC

Robin Cornelissen, MD, PhD, Erasmus University Rotterdam, Rotterdam, Netherlands, explains how the introduction of next-generation sequencing (NGS) has enabled to detect mutations in over 500 genes in non-small cell lunger cancer (NSCLC). This information is highly valuable to decide whether a patient should be included in a clinical trial. This interview took place at the European Society for Medical Oncology (ESMO) 2021 congress.

Sign-up for our Newsletter!

Keep up to date with all the latest news with our monthly newsletter